Tower Research Capital (TRC)’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$41.1K Buy
+712
New +$38.9K ﹤0.01% 3337
2026
Q2
– Sell
-1,964
Closed -$80K – 5230
2026
Q1
$80K Buy
1,964
+88
+5% +$3.65K ﹤0.01% 2362
2025
Q4
$74.8K Buy
1,876
+760
+68% +$28.1K ﹤0.01% 2147
2025
Q3
$33.2K Sell
1,116
-4,084
-79% -$110K ﹤0.01% 2855
2025
Q2
$119K Sell
5,200
-3,672
-41% -$80.8K ﹤0.01% 2239
2025
Q1
$214K Sell
8,872
-1,780
-17% -$47.7K 0.01% 1327
2024
Q4
$270K Buy
10,652
+2,532
+31% +$75K 0.01% 1497
2024
Q3
$259K Sell
8,120
-16,560
-67% -$535K 0.01% 1380
2024
Q2
$731K Buy
24,680
+24,660
+123,300% +$682K 0.01% 1013
2024
Q1
$575 Sell
20
-2,864
-99% -$83.1K ﹤0.01% 5437
2023
Q4
$82.3K Sell
2,884
-10,030
-78% -$235K ﹤0.01% 2782
2023
Q3
$310K Buy
12,914
+10,844
+524% +$279K 0.01% 1162
2023
Q2
$53.8K Sell
2,070
-5,232
-72% -$144K ﹤0.01% 2526
2023
Q1
$198K Sell
7,302
-17,810
-71% -$503K 0.01% 1377
2022
Q4
$725K Buy
25,112
+24,556
+4,417% +$691K 0.03% 511
2022
Q3
$13K Sell
556
-27,598
-98% -$736K ﹤0.01% 4256
2022
Q2
$681K Buy
28,154
+28,124
+93,747% +$716K 0.02% 939
2022
Q1
$1K Sell
30
-21,476
-100% -$659K ﹤0.01% 5747
2021
Q4
$872K Sell
21,506
-3,656
-15% -$157K 0.02% 765
2021
Q3
$1.19M Sell
25,162
-13,588
-35% -$687K 0.03% 454
2021
Q2
$1.91M Sell
38,750
-1,660
-4% -$72.4K 0.05% 327
2021
Q1
$1.69M Buy
+40,410
New +$1.91M 0.03% 543
2020
Q4
– Sell
-99,066
Closed -$3.47M – 5128
2020
Q3
$3.47M Buy
99,066
+98,666
+24,667% +$3.5M 0.04% 155
2020
Q2
$15K Sell
400
-1,360
-77% -$43.4K ﹤0.01% 3810
2020
Q1
$41K Sell
1,760
-40,906
-96% -$1.14M ﹤0.01% 1379
2019
Q4
$1.32M Buy
42,666
+33,136
+348% +$884K 0.11% 85
2019
Q3
$202K Sell
9,530
-119,460
-93% -$2.83M 0.01% 999
2019
Q2
$3.34M Buy
128,990
+109,584
+565% +$2.73M 0.23% 56
2019
Q1
$539K Sell
19,406
-33,236
-63% -$895K 0.03% 556
2018
Q4
$1.11M Sell
52,642
-1,544
-3% -$40.3K 0.08% 243
2018
Q3
$1.89M Buy
54,186
+32,794
+153% +$1.07M 0.14% 112
2018
Q2
$612K Buy
21,392
+21,070
+6,543% +$574K 0.03% 546
2018
Q1
$9K Sell
322
-95,730
-100% -$2.87M ﹤0.01% 2490
2017
Q4
$2.69M Buy
96,052
+95,922
+73,786% +$2.71M 0.35% 46
2017
Q3
$4K Sell
130
-53,992
-100% -$1.54M ﹤0.01% 3372
2017
Q2
$1.44M Buy
54,122
+38,574
+248% +$941K 0.16% 108
2017
Q1
$375K Sell
15,548
-29,462
-65% -$685K 0.04% 178
2016
Q4
$898K Sell
45,010
-57,334
-56% -$1.22M 0.1% 223
2016
Q3
$2.48M Sell
102,344
-117,322
-53% -$2.79M 0.25% 44
2016
Q2
$4.27M Buy
219,666
+34,062
+18% +$734K 0.41% 39
2016
Q1
$3.79M Buy
185,604
+132,442
+249% +$2.93M 0.56% 29
2015
Q4
$1.9M Buy
53,162
+50,488
+1,888% +$1.69M 0.31% 43
2015
Q3
$78K Sell
2,674
-14,006
-84% -$597K 0.01% 715
2015
Q2
$754K Sell
16,680
-31,576
-65% -$1.36M 0.07% 110
2015
Q1
$1.91M Sell
48,256
-53,332
-52% -$1.98M 0.24% 59
2014
Q4
$3.19M Buy
101,588
+27,524
+37% +$807K 0.31% 50
2014
Q3
$1.92M Sell
74,064
-26,236
-26% -$636K 0.22% 88
2014
Q2
$2.33M Buy
+100,300
New +$1.98M 0.3% 40

Other funds holding BIB

Tower Research Capital (TRC)'s BIB Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2026: 712 shares worth $41.1K. The stake represents ﹤0.01% of the portfolio and ranks #3337 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BIB as recently as Q1 2026.

Tower Research Capital (TRC) first reported a position in BIB in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.27M in Q2 2016. 17 funds tracked by Wall St. Rank hold BIB as of Q3 2026.

  • Tower Research Capital (TRC) held 712 shares of ProShares Ultra NASDAQ Biotechnology worth $41.1K as of Q3 2026.
  • ProShares Ultra NASDAQ Biotechnology was a new Tower Research Capital (TRC) position in Q3 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3337 holding.
  • Tower Research Capital (TRC) first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and has held it in 48 quarters since.
  • Tower Research Capital (TRC)'s ProShares Ultra NASDAQ Biotechnology position peaked at $4.27M in Q2 2016.
  • 17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.